Biogen's Aducanumab: A Look at the Drug’s History and Recent Updates

One of the big drugs investors, analysts and pretty much everyone else in the biopharma industry is keeping an eye on is Biogen and Eisai’s aducanumab for Alzheimer’s disease. If approved, it will be the first disease-modifying treatments to be approved since 2003 (AbbVie’s Namenda (memantine))—and the existing drugs have modest effects, at best.